BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barreda-Sánchez M, Buendía-Martínez J, Glover-López G, Carazo-Díaz C, Ballesta-Martínez MJ, López-González V, Sánchez-Soler MJ, Rodriguez-Peña L, Serrano-Antón AT, Gil-Ferrer R, Martínez-Romero MDC, Carbonell-Meseguer P, Guillén-Navarro E. High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor. Orphanet J Rare Dis 2019;14:59. [PMID: 30808393 DOI: 10.1186/s13023-019-1031-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Brenner DM, Brandt LJ, Fenster M, Hamilton MJ, Kamboj AK, Oxentenko AS, Wang B, Chey WD. Rare, Overlooked, or Underappreciated Causes of Recurrent Abdominal Pain: A Primer for Gastroenterologists. Clin Gastroenterol Hepatol 2023;21:264-79. [PMID: 36180010 DOI: 10.1016/j.cgh.2022.09.022] [Reference Citation Analysis]
2 Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology 2023:S0016-5085(22)01356-7. [PMID: 36642627 DOI: 10.1053/j.gastro.2022.11.034] [Reference Citation Analysis]
3 Jericó D, Córdoba KM, Sampedro A, Jiang L, Joucla G, Cabanne C, Lanciego JL, Martini PGV, Berraondo P, Ávila MA, Fontanellas A. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment. Life (Basel) 2022;12. [PMID: 36430993 DOI: 10.3390/life12111858] [Reference Citation Analysis]
4 Ghosh R, León-Ruiz M, Singh Sardar S, Naga D, Roy D, Ghosh T, Dubey S, Benito-León J. A novel heterozygous mutation in the hydroxymethylbilane synthase gene in a case with acute intermittent porphyria. Qatar Med J 2022;2022:46. [PMID: 36304064 DOI: 10.5339/qmj.2022.46] [Reference Citation Analysis]
5 Humphreys SC, Davis JA, Iqbal S, Kamel A, Kulmatycki K, Lao Y, Liu X, Rodgers J, Snoeys J, Vigil A, Weng Y, Wiethoff CM, Wittwer MB. Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics. Nucleic Acids Res 2022:gkac456. [PMID: 35687098 DOI: 10.1093/nar/gkac456] [Reference Citation Analysis]
6 Sirch C, Khanna N, Frassetto L, Bianco F, Artero ML. Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report. World J Transplant 2022; 12(1): 8-14 [DOI: 10.5500/wjt.v12.i1.8] [Reference Citation Analysis]
7 Wang B. Novel treatment options for acute hepatic porphyrias. Curr Opin Gastroenterol 2021;37:194-9. [PMID: 33769375 DOI: 10.1097/MOG.0000000000000734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Souza PVS, Badia BML, Farias IB, Gonçalves EA, Pinto WBVR, Oliveira ASB. Acute hepatic porphyrias for the neurologist: current concepts and perspectives. Arq Neuropsiquiatr 2021;79:68-80. [PMID: 33656101 DOI: 10.1590/0004-282X20200096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Buendía-Martínez J, Barreda-Sánchez M, Rodríguez-Peña L, Ballesta-Martínez MJ, López-González V, Sánchez-Soler MJ, Serrano-Antón AT, Pérez-Tomás ME, Gil-Ferrer R, Avilés-Plaza F, Glover-López G, Carazo-Díaz C, Guillén-Navarro E. Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients. Orphanet J Rare Dis 2021;16:106. [PMID: 33639982 DOI: 10.1186/s13023-021-01742-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Ma L, Tian Y, Peng C, Zhang Y, Zhang S. Recent advances in the epidemiology and genetics of acute intermittent porphyria. Intractable Rare Dis Res 2020;9:196-204. [PMID: 33139978 DOI: 10.5582/irdr.2020.03082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Chakrabarty B, Das D, Bung N, Roy A, Bulusu G. Network analysis of hydroxymethylbilane synthase dynamics. J Mol Graph Model 2020;99:107641. [PMID: 32619952 DOI: 10.1016/j.jmgm.2020.107641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Smith M. Personalized precision medicine—Part A: Concepts and relevance in Mendelian disorders. Gene Environment Interactions 2020. [DOI: 10.1016/b978-0-12-819613-7.00009-8] [Reference Citation Analysis]
13 Fontanellas A, Ávila MA, Anderson KE, Deybach JC. Current and innovative emerging therapies for porphyrias with hepatic involvement. J Hepatol 2019;71:422-33. [PMID: 31102718 DOI: 10.1016/j.jhep.2019.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]